KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Liabilities (2016 - 2025)

Jazz Pharmaceuticals has reported Total Liabilities over the past 16 years, most recently at $7.3 billion for Q4 2025.

  • Quarterly Total Liabilities fell 7.3% to $7.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 billion through Dec 2025, down 7.3% year-over-year, with the annual reading at $7.3 billion for FY2025, 7.3% down from the prior year.
  • Total Liabilities was $7.3 billion for Q4 2025 at Jazz Pharmaceuticals, down from $7.4 billion in the prior quarter.
  • Over five years, Total Liabilities peaked at $9.1 billion in Q2 2021 and troughed at $3.0 billion in Q1 2021.
  • The 5-year median for Total Liabilities is $7.7 billion (2023), against an average of $7.6 billion.
  • Biggest five-year swings in Total Liabilities: skyrocketed 210.51% in 2021 and later fell 11.92% in 2022.
  • Tracing JAZZ's Total Liabilities over 5 years: stood at $8.3 billion in 2021, then decreased by 7.01% to $7.7 billion in 2022, then decreased by 1.2% to $7.7 billion in 2023, then rose by 3.42% to $7.9 billion in 2024, then decreased by 7.3% to $7.3 billion in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $7.3 billion, $7.4 billion, and $7.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.